Cytek Biosciences (NASDAQ:CTKB) Shares Down 7.5%
Cytek Biosciences (NASDAQ:CTKB) Shares Down 7.5%
Cytek Biosciences, Inc. (NASDAQ:CTKB – Get Rating) shares dropped 7.5% during mid-day trading on Thursday . The company traded as low as $10.91 and last traded at $10.92. Approximately 9,581 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 739,450 shares. The stock had previously closed at $11.81.
赛特克生物科技股份有限公司(纳斯达克代码：CTKB-GET Rating)股价周四午盘下跌7.5%。该公司股价低至10.91美元，最新报10.92美元。午盘成交量约为9,581股，较日均成交量739,450股减少99%。该股此前收盘价为11.81美元。
Analyst Ratings Changes
分析师评级发生变化
Separately, Piper Sandler raised their price objective on Cytek Biosciences from $16.00 to $18.00 in a research report on Monday, November 14th.
另外，派珀·桑德勒在11月14日星期一的一份研究报告中将Cytek Biosciences的目标价从16.00美元上调至18.00美元。
Cytek Biosciences Price Performance
Cytek Bioscions性价比
The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of -1,181.00 and a beta of 0.06. The stock has a 50-day moving average price of $11.91 and a 200-day moving average price of $12.97.
该公司市值14.7亿美元，市盈率为-1181.00，贝塔系数为0.06。该股的50日移动均线价格为11.91美元，200日移动均线价格为12.97美元。
Insider Buying and Selling
内幕买卖
In related news, CEO Wenbin Jiang sold 20,000 shares of Cytek Biosciences stock in a transaction that occurred on Monday, November 7th. The stock was sold at an average price of $14.76, for a total transaction of $295,200.00. Following the completion of the sale, the chief executive officer now directly owns 7,785,820 shares of the company's stock, valued at approximately $114,918,703.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Cytek Biosciences news, CFO Patrik Jeanmonod sold 3,500 shares of the firm's stock in a transaction on Monday, October 24th. The stock was sold at an average price of $15.16, for a total transaction of $53,060.00. Following the transaction, the chief financial officer now owns 85,563 shares in the company, valued at approximately $1,297,135.08. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Wenbin Jiang sold 20,000 shares of the firm's stock in a transaction on Monday, November 7th. The stock was sold at an average price of $14.76, for a total value of $295,200.00. Following the transaction, the chief executive officer now owns 7,785,820 shares in the company, valued at approximately $114,918,703.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 126,500 shares of company stock valued at $1,618,745. Insiders own 15.90% of the company's stock.
在相关新闻中，首席执行官蒋文斌在11月7日星期一的一笔交易中出售了20,000股Cytek Biosciences股票。该股以14.76美元的平均价格出售，总成交金额为295,200.00美元。出售完成后，首席执行官现在直接拥有7,785,820股公司股票，价值约114,918,703.20美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过美国证券交易委员会网站。在Cytek Biosciences的其他新闻中，首席财务官Patrik Jeanmonod在10月24日星期一的一次交易中出售了3500股该公司的股票。股票以15.16美元的平均价格出售，总成交金额为53,060.00美元。交易完成后，这位首席财务官现在拥有该公司85,563股股票，价值约1,297,135.08美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。此外，首席执行官蒋文斌在11月7日星期一的一次交易中出售了2万股该公司的股票。这只股票的平均售价为14.76美元，总价值为295,200.00美元。交易完成后，这位首席执行官现在拥有该公司7,785,820股票，价值约114,918,703.20美元。关于这次销售的披露可以找到这里。在过去的90天里，内部人士抛售了126,500股公司股票，价值1,618,745美元。内部人士持有该公司15.90%的股份。
Hedge Funds Weigh In On Cytek Biosciences
对冲基金参与Cytek Bioscions
A number of hedge funds have recently added to or reduced their stakes in CTKB. Royal Bank of Canada increased its stake in shares of Cytek Biosciences by 222.0% in the 3rd quarter. Royal Bank of Canada now owns 2,074 shares of the company's stock valued at $30,000 after purchasing an additional 1,430 shares during the last quarter. UBS Group AG increased its stake in shares of Cytek Biosciences by 6,269.8% in the 3rd quarter. UBS Group AG now owns 4,013 shares of the company's stock valued at $59,000 after purchasing an additional 3,950 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Cytek Biosciences by 54.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 5,077 shares of the company's stock valued at $74,000 after purchasing an additional 1,789 shares during the last quarter. Metropolitan Life Insurance Co NY increased its stake in shares of Cytek Biosciences by 31.5% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 6,415 shares of the company's stock valued at $69,000 after purchasing an additional 1,536 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Cytek Biosciences in the 2nd quarter valued at $70,000. Institutional investors own 49.48% of the company's stock.
一些对冲基金最近增持或减持了CTKB的股份。加拿大皇家银行在第三季度增持赛特克生物科学股份222.0。加拿大皇家银行在上个季度又购买了1,430股，现在持有该公司2,074股股票，价值3万美元。瑞银集团(UBS Group AG)第三季度增持Cytek Biosciences股份6,269.8%。瑞银集团目前持有该公司4,013股股票，价值59,000美元，上一季度又购买了3,950股。AllSpring Global Investments Holdings LLC在第三季度增持了Cytek Biosciences的股份54.4%。AllSpring Global Investments Holdings LLC现在持有该公司5,077股股票，价值7.4万美元，上个季度又购买了1,789股。纽约大都会人寿保险公司在第一季度增持了Cytek Biosciences的股份31.5%。纽约大都会人寿保险公司目前持有6,415股该公司股票，价值6.9万美元，此前该公司在上个季度又购买了1,536股。最后，Lazard Asset Management LLC在第二季度购买了价值7万美元的Cytek Biosciences股票的新头寸。机构投资者持有该公司49.48%的股份。
Cytek Biosciences Company Profile
赛特克生物科学公司简介
(Get Rating)
(获取评级)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis.
Cytek Biosciences，Inc.是一家细胞分析解决方案公司，提供细胞分析工具，促进生物医学研究和临床应用的科学进步。它提供极光和北极光系统，这是一种光谱流动细胞仪，通过利用来自多个激光的荧光信号来区分单个细胞上的荧光标记来提供细胞分析；以及极光细胞分选系统，它利用全光谱图谱技术进一步拓宽了细胞分析的潜在应用。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Cytek Biosciences (CTKB)
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- More Than One Reason To Buy Fastenal, Quickly
- 3 Attractive Defensive Stocks With 3% Dividends
- 免费获取StockNews.com关于Cytek生物科学的研究报告(CTKB)
- 爱彼迎的涨幅是否会像分析师预测的那样达到38%？
- 特斯拉汽车降价是否意味着特斯拉股票也会降价？
- 微软的裁员标志着其他科技公司的裁员？
- 快速购买Fastenal的原因不止一个
- 3只有吸引力的防御性股票，股息为3%
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Cytek生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cytek Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。